Efficacy and Tolerability of the New Antiepileptic Drugs, I: Treatment of New‐Onset Epilepsy: Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society

@article{French2004EfficacyAT,
  title={Efficacy and Tolerability of the New Antiepileptic Drugs, I: Treatment of New‐Onset Epilepsy: Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society},
  author={Jacqueline A. French and Andres M. Kanner and Jocelyn F. Bautista and Bassel Abou-Khalil and Thomas R. Browne and Cynthia L. Harden and William H. Theodore and Carl W. Bazil and John M. Stern and Steven C. Schachter and Donna C. Bergen and Deborah G. Hirtz and Georgia D. Montouris and Mark Nespeca and Barry E. Gidal and William J Marks and William R. Turk and James Fischer and Blaise F. D. Bourgeois and Andrew Wilner and R. Faught and Rajesh C. Sachdeo and Ahmad Beydoun and Tracy A. Glauser},
  journal={Epilepsia},
  year={2004},
  volume={45}
}
Summary:  Purpose: To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs [AEDs; gabapentin (GBP), lamotrigine (LTG), topiramate (TPM), tiagabine (TGB), oxcarbazepine (OXC), levetiracetam (LEV), and zonisamide (ZNS), reviewed in the order in which these agents received approval by the U.S. Food and Drug Administration] in the treatment of children and adults with newly diagnosed partial and generalized epilepsies. 
Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society
TLDR
The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with newly diagnosed epilepsy and identify those seizure types and syndromes where more evidence is necessary.
A Clinical Overview of the New Antiepileptic Drugs
TLDR
All the new anti-epileptic drugs are also effective as add-on therapy for partial seizures without or with secondary generalization.
New antiepileptic drugs in pediatric epilepsy
TLDR
This work reviews the mechanisms of action, pharmacokinetic properties, adverse reactions, efficacy, and tolerability of eight new AEDs, focusing on currently available treatment guidelines and expert opinions regarding pediatric epilepsy.
Review article New antiepileptic drugs in pediatric epilepsy
TLDR
This work reviews the mechanisms of action, pharmacokinetic properties, adverse reactions, efficacy, and tolerability of eight new AEDs, focusing on currently available treatment guidelines and expert opinions regarding pediatric epilepsy.
Traditional versus new antiepileptic drugs
TLDR
The characteristics, prognosis, and choices of antiepileptic drugs (AED) in common syndromes of IGE, a genetic based seizures with normal neurologic exam, intelligence, and imaging studies, are summarized.
Novel anticonvulsant drugs.
TLDR
Different aspects of new anticonvulsant drugs (2nd generation) from preclinical and clinical testing, pharmacokinetics, interactions, indications and dosages as well as side effects are summarized.
Review Article) New antiepileptic drugs in children with epilepsy
TLDR
The mechanisms of action, indications, pharmacokinetics, dosing, and safety profiles of the new AEDs in children with epilepsy, and the principles of AED selection for children will be discussed.
Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines
  • E. Beghi
  • Medicine
    The Lancet Neurology
  • 2004
TLDR
Comparative, pragmatic, long-term and open trials should be done to show long- term efficacy and comparative features of the new antiepileptic drugs, and to better assess the effect on quality-of-life, cost-effectiveness, tolerability, and teratogenic potential.
Zonisamide: newer antiepileptic agent with multiple mechanisms of action
  • V. Biton
  • Medicine
    Expert review of neurotherapeutics
  • 2004
TLDR
Zonisamide has multiple mechanisms of action, which may explain widespread reports of its utility in focal epilepsy and generalized epilepsy, and for nonseizure disorders such as headache and neuropathic pain.
Use of New Generation Antiepileptic Drugs in Children
TLDR
Aim of epilepsy management is to cure seizure and to maintain a good quality of life, three important drug properties need to be considered: efficacy, tolerability and safety.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 112 REFERENCES
New antiepileptic drugs: a systematic review of their efficacy and tolerability
TLDR
Each drug was significantly better than placebo at preventing seizures, but none was significantly different from the others in terms of efficacy or tolerability, though the confidence intervals were wide Randomised trials comparing active treatments are needed to further evaluate these drugs.
Lamotrigine Monotherapy in Newly Diagnosed Untreated Epilepsy: A Double‐Blind Comparison with Phenytoin
TLDR
Lamotrigine is an effective add‐on therapy against a range of epileptic seizure types and Comparative studies with carbamazepine as monotherapy in newly diagnosed epilepsy suggest similar efficacy.
Topiramate in the Long‐Term Management of Refractory Epilepsy
TLDR
Patients with partial and/or generalized seizures previously resistant to antiepileptic drug (AED) therapy were treated with open‐label topiramate (TPM) in dosages of 100–1,600 mg/day.
Efficacy and safety of topiramate in refractory epilepsy: a long-term prospective trial
TLDR
Topiramate is a valuable agent for the long-term management of refractory epilepsy and withdrawal of treatment was required in six cases as a result of ataxia.
An active-control trial of lamotrigine monotherapy for partial seizures
TLDR
LTG is effective and well tolerated when administered as monotherapy in adult patients with partial seizures, and the incidence of adverse events during the monotherapy period was lower than during the transition period.
The Long‐Term Use of Gabapentin, Lamotrigine, and Vigabatrin in Patients with Chronic Epilepsy
TLDR
To assess the likelihood of seizure freedom, seizure‐related injury/hospital admission and mortality after these drugs were commenced, gabapentin, lamotrigine, and vigabatrin were commenced.
The effects of adjunctive topiramate therapy on seizure severity and health-related quality of life in patients with refractory epilepsy—a Canadian study
TLDR
The results indicate that topiramate significantly reduces seizure severity---an important aspect of HRQL---when administered as adjunctive therapy to anticonvulsant therapy.
Effectiveness of First Antiepileptic Drug
TLDR
The interaction among efficacy, tolerability, and overall effectiveness of the first antiepileptic drug (AED) in patients with newly diagnosed epilepsy is investigated.
Lamotrigine Therapy for Partial Seizures: A Multicenter, Placebo‐Controlled, Double‐Blind, Cross‐Over Trial
TLDR
The addition of twice‐daily LTG to an existing AED regimen was safe, effective, and well tolerated in these medically refractory partial seizure patients.
Gabapentin (Neurontin) as Add‐on Therapy in Patients with Partial Seizures: A Double‐Blind, Placebo‐Controlled Study
TLDR
GBP is safe and effective in treating some patients with refractory partial seizures and no clinically important trends and no evidence of hepatic or hematopoietic effects are shown.
...
1
2
3
4
5
...